-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOAGE LABS ANNOUNCES FIRST PARTICIPANT DOSED IN QUELL-CV, A PHASE 2 PROOF-OF-CONCEPT TRIAL OF BGE-102, A NOVEL ORAL NLRP3 INHIBITOR, IN PATIENTS AT ELEVATED CARDIOVASCULAR RISK

Reuters·06/16/2026 12:00:01

Please log in to view news